Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol in Inclusion Body Myositis
NCT02753530Phase 2Completed
- Sponsor
- Zevra Therapeutics
- Start
- Aug 2017
- Primary completion
- Jan 2021
- Countries
- 2
01
Overview
A Phase 2 trial of arimoclomol in inclusion body myositis (IBM), sponsored by Zevra Therapeutics. Started Aug 2017; status: completed.
02
Drugs
arimoclomol
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT02753530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753530.